Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

Buzdar, A, Jonat, W, Howell, A, Jones, S E, Blomqvist, C, Vogel, C L, Eiermann, W, Wolter, J M, Azab, M, Webster, A, Plourde, P V·1996·Journal of Clinical Oncology
DOI 10.1200/jco.1996.14.7.2000

Cited by (406)

Items 101–200 of 406

  1. Application of Metabolomics in Drug Resistant Breast Cancer Research
    Ayesha N. Shajahan‐Haq, Mehar Cheema, Robert C. Clarke · 2015 · Metabolites
  2. The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment
    Mohamed FM Mitwally, Robert F. Casper, Michael P. Diamond · 2005 · Reproductive Biology and Endocrinology
  3. Risks versus benefits in the clinical application of aromatase inhibitors.
    Paul Edward Goss · 1999 · Endocrine Related Cancer
  4. A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
    Hiroji Iwata, Norikazu Masuda, Shinji Ohno, Yoshiaki Rai, Yasuyuki Sato, Shozo Ohsumi, Satoshi Hashigaki, Yoshinori Nishizawa, Masahiro Hiraoka, Tadaoki Morimoto et al. · 2013 · Breast Cancer Research and Treatment
  5. Role of aromatase inhibitors in breast cancer
    R Carpenter, William R. Miller · 2005 · British Journal of Cancer
  6. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
    W. Jonat, Thomas Bachelot, Thomas Ruhstaller, Iris Kuss, U. Reimann, John F. R. Robertson · 2013 · Annals of Oncology
  7. The Preliminary Study of 16α-[18F]fluoroestradiol PET/CT in Assisting the Individualized Treatment Decisions of Breast Cancer Patients
    Yifei Sun, Zhongyi Yang, Yongping Zhang, Jing Xue, Mingwei Wang, Wei Shi, Beiling Zhu, Silong Hu, Zhifeng Yao, Herong Pan et al. · 2015 · PLoS ONE
  8. Recent advances in endocrine therapy of breast cancer
    Anthony Howell, Mitch Dowsett · 1997 · BMJ
  9. Aromatase inhibitors and breast cancer
    William R. Miller · 1997 · Cancer Treatment Reviews
  10. An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial
    Mattias Neyt, Johan Albrecht, V.F.J. Cocquyt · 2005 · Annals of Oncology
  11. The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial
    Harriet Richardson, D. Johnston, Joseph L. Pater, Paul Edward Goss · 2007 · Current Oncology
  12. Endocrine Therapy for Advanced/Metastatic Breast Cancer
    Gaia Schiavon, Ian E. Smith · 2013 · Hematology/Oncology Clinics of North America
  13. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer
    Neill Patani, Lesley‐Ann Martin · 2013 · Molecular and Cellular Endocrinology
  14. Dose-Response Trial of Megestrol Acetate in Advanced Breast Cancer: Cancer and Leukemia Group B Phase III Study 8741
    Jeffrey S. Abrams, Joseph Aisner, Constance Cirrincione, Donald A. Berry, Hyman Bernard Muss, M. Robert Cooper, I. Craig Henderson, Lawrence Panasci, Jeffrey Kirshner, John Allan Ellerton et al. · 1999 · Journal of Clinical Oncology
  15. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
    other Goim authors, R. V. Iaffaioli, Roberta Formato, Anna Tortoriello, S. Del Prete, Michele Caraglia, Giovanni Luigi Pappagallo, Agata Pisano, F Fanelli, Giovanni Pietro Ianniello et al. · 2005 · British Journal of Cancer
  16. Metastatic Breast Cancer
    S.M. Ali, Harold A. Harvey, Allan Lipton · 2003 · Clinical Orthopaedics and Related Research
  17. Quality of systematic reviews used in guidelines for oncology practice
    Federica Vigna‐Taglianti, Paolo Vineis, Alessandro Liberati, Fabrizio Faggiano · 2006 · Annals of Oncology
  18. Challenges in the endocrine management of breast cancer
    Henning T. Mouridsen, Carsten Rose, Angela Brodie, Ian E. Smith · 2003 · The Breast
  19. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer
    Mitch Dowsett, Debbie Doody, Stephanie Miall, Angela J. Howes, Jaquie English, R. Charles Coombes · 1999 · Breast Cancer Research and Treatment
  20. Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism
    Emilio Bajetta, Antonia Martinetti, Nicoletta Zilembo, Paola Pozzi, Ignazia La Torre, L. Ferrari, Ettore Cesare Seregni, R. Longarini, G. Salvucci, Emilio Bombardieri · 2002 · Annals of Oncology
  21. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
    Mitch Dowsett, Jeffrey S. Tobias, Anthony Howell, Glen Blackman, Hazel Welch, Nicholas C. King, Riccardo Ponzone, Mia von Euler, Michael Baum · 1998 · British Journal of Cancer
  22. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
    Victor G. Vogel, Joseph P. Costantino, Donald Lawrence Wickerham, Walter M. Cronin · 2003 · PubMed
  23. Principles of Cancer Chemotherapy
    Reginald B. Ewesuedo, Mark J. Ratain · 2003 · Springer eBooks
  24. Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Sohita Dhillon · 2013 · Drugs
  25. General mechanisms of metastasis
    Elisa C. Woodhouse, Rodrigo F. Chuaqui, Lance A. Liotta · 1997 · Cancer
  26. Risks and Benefits of Aromatase Inhibitors in Postmenopausal Breast Cancer
    Laura Boehnke Michaud, Aman U. Buzdar · 1999 · Drug Safety
  27. Uterine Sarcoma and Aromatase Inhibitors
    Alon D. Altman, Gregg S Nelson, Pamela Chu, Jill G. Nation, Prafull Ghatage · 2012 · International Journal of Gynecological Cancer
  28. The therapeutic potential of aromatase inhibitors
    WR Miller, J Jackson · 2003 · Expert Opinion on Investigational Drugs
  29. A Review of the Efficacy of Anastrozole in Postmenopausal Women with Advanced Breast Cancer with Visceral Metastases
    Anthony Howell, John F.R. Robertson, Ignace B. Vergote · 2003 · Breast Cancer Research and Treatment
  30. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
    Richard Sainsbury · 2004 · British Journal of Cancer
  31. Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models
    Shannon F. Cope, Mario Ouwens, Jeroen Paul Jansen, Peter Schmid · 2013 · Value in Health
  32. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer
    John F.R. Robertson, Anthony Howell, Aman U. Buzdar, Mia von Euler, D. Lee · 1999 · Breast Cancer Research and Treatment
  33. Vascular effects of aromatase inhibitors: Data from clinical trials
    Anthony Howell, Jack M. Cuzick · 2005 · The Journal of Steroid Biochemistry and Molecular Biology
  34. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
    Iman Doostan, Cansu Karakaş, Mehrnoosh Kohansal, Kwang-Hui Low, Matthew J. Ellis, John A. Olson, Vera Jean Suman, Kelly K. Hunt, Stacy Moulder, Khandan Keyomarsi · 2017 · Clinical Cancer Research
  35. Breast cancer (metastatic).
    Justin Stebbing, Jeremy Crane, Andy Gaya · 2002 · Europe PMC (PubMed Central)
  36. Can Fluorine-18 Fluoroestradiol Positron Emission Tomography–Computed Tomography Demonstrate the Heterogeneity of Breast Cancer In Vivo?
    Zhongyi Yang, SUN Yifei, 张勇平, Jing Xue, Mingwei Wang, Wei Shi, Beiling Zhu, Silong Hu, Zhifeng Yao, Herong Pan et al. · 2013 · Clinical Breast Cancer
  37. NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared with Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor—Positive Breast Cancer
    Eleftherios P. Mamounas, Barry C. Lembersky, Jong‐Hyeon Jeong, Walter M. Cronin, Barbara Harkins, Charles E. Geyer, Donald Lawrence Wickerham, Soonmyung Paik, Joseph P. Costantino, Norman Wolmark · 2006 · Clinical Breast Cancer
  38. Estrogen-Metabolizing Enzymes in Breast Cancers from Women over the Age of 80 Years
    Naoko Honma, Kaiyo Takubo, Motoji Sawabe, Tomio Arai, Futoshi Akiyama, Goi Sakamoto, Toshiaki Utsumi, Noriko Yoshimura, Nobuhiro Harada · 2006 · The Journal of Clinical Endocrinology & Metabolism
  39. Anastrozole
    Catherine Margaret Kelly, Aman U. Buzdar · 2010 · Expert Opinion on Drug Safety
  40. Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the Combination
    J. M. Xanthopoulos, A. E. Romano, S. K. Majumdar · 2005 · BioMed Research International
  41. Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors
    Emilio Bajetta, Nicoletta Zilembo, Ettore Bichisao, Antonia Martinetti, Roberto Buzzoni, Paola Pozzi, Paolo Bidoli, L. Ferrari, Luigi Celio · 2000 · Annals of Oncology
  42. An Emerging Respect for Palliative Care in Radiation Oncology
    Nora Anita Janjan · 1998 · Journal of Palliative Medicine
  43. Germline Genetic Predictors of Aromatase Inhibitor Concentrations, Estrogen Suppression and Drug Efficacy and Toxicity in Breast Cancer Patients
    Daniel L. Hertz, Norah Lynn Henry, James Michael Rae · 2017 · Pharmacogenomics
  44. Importance of local aromatase activity in hormone-dependent breast cancer: a review
    Paul C. de Jong, Marinus A. Blankenstein, J. van de Ven, Johan W.R. Nortier, Geert H. Blijham, J.H.H. Thijssen · 2001 · The Breast
  45. Tamoxifen--the treatment of choice. Why look for alternatives?
    Michael Baum · 1998 · British Journal of Cancer
  46. Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor–Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action
    Stefan Glück · 2013 · Clinical Breast Cancer
  47. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: Focus on clinical trials and perspectives
    Joseph Gligorov, D. Azria, Moïse Namer, David Khayat, Jean‐Philippe Spano · 2007 · Critical Reviews in Oncology/Hematology
  48. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
    Stine Hole, ASTRID M. PEDERSEN, Susanne Kofoed Hansen, Johan Lundqvist, Christina Westmose Yde, Anne E. Lykkesfeldt · 2015 · International Journal of Oncology
  49. Are all aromatase inhibitors the same? A review of the current evidence
    Fritz Jänicke · 2004 · The Breast
  50. Pharmacological and clinical profile of anastrozole
    Per Eystein Lønning, Jürgen Geisler, Mitch Dowsett · 1998 · Breast Cancer Research and Treatment
  51. Positron emission tomography in the staging and management of breast cancer
    A M Byrne, Arnold D. K. Hill, Stephen J. Skehan, Enda W.M. McDermott, N. J. O’Higgins · 2004 · British journal of surgery
  52. Molecular characterization of breast cancer cell response to metabolic drugs
    Lucía Trilla‐Fuertes, Angelo Gámez‐Pozo, Jorge M. Arevalillo, Mariana Díaz‐Almirón, Guillermo Prado-Vázquez, Andrea Zapater‐Moros, Hilario Navarro, Rosa Aras‐López, Irene Dapía, Rocío López‐Vacas et al. · 2018 · Oncotarget
  53. Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression
    Yu‐An Huang, Donghai Jiang, Meihua Sui, Xiaojia Wang, Weimin Fan · 2016 · Oncology Reports
  54. Recent perspectives of endocrine therapy for breast cancer
    Toshiaki Utsumi, Naomi Kobayashi, Hidetaka Hanada · 2007 · Breast Cancer
  55. Atypical ubiquitin-binding protein SHARPIN promotes breast cancer progression
    Zelin Tian, Jianing Tang, Qian Yang, Xin Li, Jian Zhu, Gaosong Wu · 2019 · Biomedicine & Pharmacotherapy
  56. Sequential Hormonal Therapy for Metastatic Breast Cancer after Adjuvant Tamoxifen or Anastrozole
    Robert W. Carlson, I. Craig Henderson · 2003 · Breast Cancer Research and Treatment
  57. Aromatase Inhibitors for Breast Cancer: Proven Efficacy Across the Spectrum of Disease
    Christina Isabella Herold, Kimberly Blackwell · 2008 · Clinical Breast Cancer
  58. The role of aromatase inhibitors in the treatment of metastatic breast cancer
    Henning T. Mouridsen · 2003 · Seminars in Oncology
  59. Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index
    Mu-Tai Liu, Wentao Huang, Ai-Yih Wang, Chia-Chun Huang, Chao‐Yuan Huang, Tung‐Hao Chang, Chu-Pin Pi, Hao-Han Yang · 2009 · Supportive Care in Cancer
  60. Aromatase inhibitors in breast cancer therapy
    Robert W. Brueggemeier · 2002 · Expert Review of Anticancer Therapy
  61. Aromatase inhibitors: a dose-response effect?
    Ian E. Smith · 1999 · Endocrine Related Cancer
  62. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data
    S. Duffy, T.L. Jackson, Mark Lansdown, K. Philips, Michael L. Wells, S. Pollard, Glen Clack, Jack M. Cuzick, Michel Coibion, Angelo Raffaele Bianco · 2003 · BJOG An International Journal of Obstetrics & Gynaecology
  63. Tamoxifen Resistant and Refractory Breast Cancer
    Paul Edward Goss, Kathrin Strasser · 2002 · Drugs
  64. Photoinduced Hydrogen Atom Transfer Activation of Benzylic C−H Bonds Functionalization
    Guozhe Guo, Wen‐Duo Li · 2025 · Advanced Synthesis & Catalysis
  65. Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients
    Anna Tessari, Serena Di Cosimo, Dario Palmieri · 2013 · Pharmacogenomics and Personalized Medicine
  66. Model‐Based Dose Selection for Intravaginal Ring Formulations Releasing Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis Symptoms
    Isabel Reinecke, Marcus‐Hillert Schultze‐Mosgau, R. Nave, Heinz Schmitz, Bart A. Ploeger · 2016 · The Journal of Clinical Pharmacology
  67. Breast Cancer: 45 Years of Research and Progress
    Gabriel N. Hortobágyi · 2020 · Journal of Clinical Oncology
  68. The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors
    R. Stuart‐Harris, Bruce Shadbolt, Charlotte Palmqvist, Hilary A. Chaudri Ross · 2009 · The Breast
  69. Role of aromatase inhibitors in advanced breast cancer.
    Aman U. Buzdar · 1999 · Endocrine Related Cancer
  70. Significance of immunohistochemical assessment of steroid hormone receptor status for breast cancer patients
    Masafumi Kurosumi · 2003 · Breast Cancer
  71. Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review
    Jennifer A. Flemming, Yolanda Madarnas, Jacob A. Franek · 2008 · Breast Cancer Research and Treatment
  72. Exemestane in advanced breast cancer
    Aman U. Buzdar · 2000 · Anti-Cancer Drugs
  73. MANAGEMENT OF ADVANCED BREAST CANCER WITH ENDOCRINE THERAPY: THE ROLE OF THE PRIMARY HEALTHCARE TEAM
    Theobald Aj · 2000 · International Journal of Clinical Practice
  74. The current status of aromatase inhibitors in the management of breast cancer
    Michael Baum, Aman U. Buzdar · 2003 · Surgical Clinics of North America
  75. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
    Christy Ann Russell, Stephanie Green, Joe M. O’Sullivan, Harry E. Hynes, G. T. Budd, J E Congdon, Silvana Martino, Charles Kent Osborne · 1997 · Journal of Clinical Oncology
  76. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
    Paul Edward Goss · 2001 · PubMed
  77. Aromatase inhibitors as adjuvant treatment of breast cancer
    Jürgen Geisler, Per Eystein Lønning · 2005 · Critical Reviews in Oncology/Hematology
  78. Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
    Martine J Piccart, L M Parker, Kathleen I. Pritchard · 2003 · Annals of Oncology
  79. ARIMIDEX: a Potent and Selective Aromatase Inhibitor for the Treatment of Advanced Breast Cancer
    Aman U. Buzdar, W. Jonat, Anthony Howell, Paul V. Plourde · 1997 · The Journal of Steroid Biochemistry and Molecular Biology
  80. Liarozole Fumarate (R85246): In the Treatment of ER Negative, Tamoxifen Refractory or Chemotherapy Resistant Postmenopausal Metastatic Breast Cancer
    Paul Edward Goss, Kathrin Strasser, Ricardo José Marques, Mark J. Clemons, Amit M. Oza, Rakesh Goel, Martin E. Blackstein, Leonard Kaizer, Ernest E. Sterns, Jean‐Marc Nabholtz et al. · 2000 · Breast Cancer Research and Treatment
  81. Telomerase activity of cultured human pancreatic carcinoma cell lines correlates with their potential for migration and invasion
    Norihiro Sato, Naoki Maehara, Kazuhiro Mizumoto, Eishi Nagai, Takahiro Yasoshima, Koichi Hirata, Masao Tanaka · 2001 · Cancer
  82. A summary of second-line randomized studies of aromatase inhibitors
    Aman U. Buzdar · 2001 · The Journal of Steroid Biochemistry and Molecular Biology
  83. Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer
    Paul Edward Goss, Amit M. Oza, Rakesh Goel, Jean‐Marc Nabholtz, Roland De Coster, J. Bruynseels, Caroline Reid, Nancy A. T. Wadden, Michael Crump, L. Tye · 2000 · Breast Cancer Research and Treatment
  84. Exemestane Improves Survival in Metastatic Breast Cancer: Results of a Phase III Randomized Study
    Manfred Kaufmann, Emilio Bajetta, Luc Yves Dirix, Luis Enrique Fein, Stephen E. Jones, Nicoletta Zilembo, Jean-Louis Dugardyn, Cristina Nasurdi, Robert Gary Mennel, Jožica Červek et al. · 2000 · Clinical Breast Cancer
  85. A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen
    Lindsey A. Gumbrell, Thomas R. Jeffry Evans, Robert Edward Coleman, Ian E. Smith, C.J. Twelves, Michael Soukop, DW Rea, Helena Margaret Earl, Anthony Howell, Alison Louise Jones et al. · 2004 · Cancer Chemotherapy and Pharmacology
  86. Cellular and molecular mechanisms of action of bisphosphonates
    Michael J. Rogers, Sharon Gordon, Helena L. Benford, Fraser P. Coxon, Steven Paul Luckman, Jukka Mönkkönen, Julie C. Frith · 2000 · Cancer
  87. Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer
    Sumanta Kumar Pal, M. E. Dehaven, Rebecca A. Nelson, Susan H. Onami, Joann Hsu, Sarah Waliany, Laura L. Kruper, Joanne E. Mortimer · 2012 · BMC Cancer
  88. Use of Aromatase Inhibitors as First-and Second-Line Medical Therapy in Patients With Endometrial Adenocarcinoma: A Retrospective Study
    Alon D. Altman, Jennifer Anne Thompson, Gregg S Nelson, Pamela Chu, Jill G. Nation, Prafull Ghatage · 2012 · Journal of Obstetrics and Gynaecology Canada
  89. Yuehchukene, a Bis-Indole Alkaloid, and Cyclophosphamide Are Active in Breast Cancer in vitro
    Thomas W. T. Leung, G. Cheng, Chung Hin Chui, S. Ho, Fung Yi Lau, J.K.J. Tjong, T.C.C. Poon, Johnny Cheuk On Tang, Winston C. Tse, Kin Fai Cheng et al. · 1999 · Chemotherapy
  90. The prevention of breast cancer
    R S Prichard, A. D. K. Hill, Birgit Dijkstra, Enda W.M. McDermott, N. J. O’Higgins · 2003 · British journal of surgery
  91. Surveillance after potentially curative cancer treatment
    Frank E. Johnson · 1997 · Journal of Surgical Oncology
  92. Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
    Αngeliki Andrikopoulou, Oraianthi Fiste, Michalis Liontos, Meletios Athanasios Dimopoulos, Flora Zagouri · 2021 · Cancers
  93. Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer
    Lisa Flaum, William John Gradishar · 2018 · Cancer treatment and research
  94. A Comparison of the Efficacy of Aromatase Inhibitors in Second-Line Treatment of Metastatic Breast Cancer
    Carsten Rose · 2003 · American Journal of Clinical Oncology
  95. Update on clinical role of tamoxifen
    John R. Benson, Vassilis Pitsinis · 2003 · Current Opinion in Obstetrics & Gynecology
  96. Hormone Replacement Therapy in Breast Cancer Survivors
    David A. Decker, Jane Pettinga, Timothy C. Cox, John H. Burdakin, Ishmael A. Jaiyesimi, Pamela R. Benitez · 1997 · The Breast Journal
  97. Living with advanced breast cancer: development and application of a clinical checklist for patients on endocrine therapy
    Penelope Hopwood · 1998 · The Breast
  98. Aromatase Inhibition in Obese Women: How Much Is Enough?
    Jennifer A. Ligibel, Eric P. Winer · 2012 · Journal of Clinical Oncology
  99. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole
    Ioannis Kyvernitakis, Dana Knöll, Maggie B. Struck, Olaf Hars, T. Bauer, Peyman Hadji · 2013 · Journal of Cancer Research and Clinical Oncology
  100. Clinical outcome for patients of solitary bone only metastasis
    Seiichi Hosaka, Hirohisa Katagiri, Yosuke Honda, Junji Wasa, Hideki Murata, Mitsuru Takahashi · 2016 · Journal of Orthopaedic Science